Bibliography
- Treatment of mycobacterial infections. Available from: http://www.who.int/tb/en/
- Ross JE, Anderegga TR, Sader HS, et al. Trends in linezolid susceptibility patterns in 2002: reports from the worldwide Zyvox annual appraisal of potency and spectrum program. Diag Microbiol Infect Dis 2005;52:53-8
- Phillips OA, Udo EE, Ali AAM, Hassawi NAL. Synthesis and antibacterial activity of 5-substituted oxazolidinones. Bioorg Med Chem 2003;11:35-41
- Reck F, Zhou F, Girardot M, et al. Indentification of 4-substituted 1,2,3-triazoles as new oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J Med Chem 2005;48:499-506
- AstraZeneca AB. AstraZeneca UK Ltd. Oxazolidinone derivatives with antibiotic activity. WO081350; 2001
- RIB-X Pharmaceuticals. Macrocyclic compounds and methods of making and using the same. WO118610; 2005
- RIB-X Pharmaceuticals. Bifunctional macrolide heterocyclic compounds and methods of making and using the same. WO049632; 2005
- RIB-X Pharmaceuticals. Macrocyclic compounds and methods of making and using the same. WO085266; 2005
- Brickner SJ, Hutchinson DK, Barbachym MR, et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem 1996;39:673-9
- De Souza MVN. Promising drugs against tuberculosis. Recent Patents Antiinfective Drug Discov 2006;1:33-45
- Huisgen R. Kinetics and mechanism of 1,3-dipolar cycloadditions. Angew Chem Int Ed 1963;2(11):633-45
- Hartmuth KC, Sharpless B. The growing impact of click chemistry on drug discovery. DDT 2003;8(24):1128-37